SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

INTRODUCTION: The use of immune-checkpoint inhibitors has drastically improved the management of patients with non-small cell lung cancer (NSCLC), but innate and acquired resistances are hurdles needed to be solved. Immunomodulatory drugs that can reinvigorate the immune cytotoxic activity, in combi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Immunother Cancer
Hlavní autoři: Redin, Esther, Garmendia, Irati, Lozano, Teresa, Serrano, Diego, Senent, Yaiza, Redrado, Miriam, Villalba, Maria, De Andrea, Carlos E, Exposito, Francisco, Ajona, Daniel, Ortiz-Espinosa, Sergio, Remirez, Ana, Bertolo, Cristina, Sainz, Cristina, Garcia-Pedrero, Juana, Pio, Ruben, Lasarte, Juan, Agorreta, Jackeline, Montuenga, Luis M, Calvo, Alfonso
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2021
Témata:
Clinical/Translational Cancer Immunotherapy
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7931761/
https://ncbi.nlm.nih.gov/pubmed/33658304
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001496
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky